250 related articles for article (PubMed ID: 16020669)
1. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H
Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669
[TBL] [Abstract][Full Text] [Related]
2. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
3. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
4. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
5. IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells.
Watanabe M; Dewan MZ; Taira M; Shoda M; Honda M; Sata T; Higashihara M; Kadin ME; Watanabe T; Yamamoto N; Umezawa K; Horie R
Lab Invest; 2007 Apr; 87(4):372-82. PubMed ID: 17310217
[TBL] [Abstract][Full Text] [Related]
6. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
8. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R
Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280
[TBL] [Abstract][Full Text] [Related]
10. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
Dabaghmanesh N; Matsubara A; Miyake A; Nakano K; Ishida T; Katano H; Horie R; Umezawa K; Watanabe T
Cancer Sci; 2009 Apr; 100(4):737-46. PubMed ID: 19469019
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
Ramos PMM; Pezuk JA; Castro-Gamero AM; Oliveira HF; Scrideli CA; Umezawa K; Tone LG
Anticancer Agents Med Chem; 2018; 18(4):541-549. PubMed ID: 29141555
[TBL] [Abstract][Full Text] [Related]
12. 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo.
Ito K; Nakazato T; Xian MJ; Yamada T; Hozumi N; Murakami A; Ohigashi H; Ikeda Y; Kizaki M
Cancer Res; 2005 May; 65(10):4417-24. PubMed ID: 15899834
[TBL] [Abstract][Full Text] [Related]
13. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
[TBL] [Abstract][Full Text] [Related]
14. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
[TBL] [Abstract][Full Text] [Related]
15. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
Meng Z; Mitsutake N; Nakashima M; Starenki D; Matsuse M; Takakura S; Namba H; Saenko V; Umezawa K; Ohtsuru A; Yamashita S
Endocrinology; 2008 Nov; 149(11):5357-65. PubMed ID: 18653704
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.
Miyake A; Dewan MZ; Ishida T; Watanabe M; Honda M; Sata T; Yamamoto N; Umezawa K; Watanabe T; Horie R
Microbes Infect; 2008 Jun; 10(7):748-56. PubMed ID: 18538617
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
Yasuda A; Kondo S; Nagumo T; Tsukamoto H; Mukudai Y; Umezawa K; Shintani S
Oral Oncol; 2011 May; 47(5):334-9. PubMed ID: 21459660
[TBL] [Abstract][Full Text] [Related]
20. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR; Ma HM; Vescio R
Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
